Cue Biopharma Names Dominic Borie as Chief Medical Officer and R&D Head Strengthens Leadership as Immunology Pipeline Advances

Cue Biopharma has appointed Dominic Borie, M.D., Ph.D. as its new Chief Medical Officer and Head of Research & Development. Reporting directly to President and CEO Shao-Lee Lin, M.D., Ph.D., Dr. Borie will lead the company's clinical and research strategy as it advances therapies for immune-mediated diseases.

The appointment comes as Cue Biopharma progresses several key programs within its immunology pipeline. The company expects to report Phase 2 data for CUE-221 in chronic spontaneous urticaria (CSU) by the end of the third quarter of 2026. It also remains on track to initiate a Phase 1 trial for CUE-401, a first-in-class bifunctional IL-2 and TGF-β molecule being developed for potential use across multiple autoimmune diseases, by the end of the fourth quarter of 2026. Earlier this year, Cue announced a $50 million private placement to support ongoing clinical development activities.

"I am excited to join Cue at such an important time for the company," said Dr. Borie. "The combination of a differentiated pipeline, a talented and mission-driven team, a solid financial foundation and the opportunity to bring meaningful new therapies to patients with allergic and autoimmune diseases is incredibly compelling. I look forward to working alongside my colleagues to thoughtfully progress on our clinical programs and help realize the full potential of our science for patients."

Dr. Borie brings more than 20 years of experience in biotechnology and pharmaceutical research and development. He most recently served as a Strategic Advisor to the CEO and Board of Kyverna Therapeutics, where he previously held the positions of President of Research & Development and founding CEO. During his career, he has also held senior leadership roles at Horizon Therapeutics, Genentech, Amgen, and Roche, overseeing immunology programs from early-stage research through global clinical studies.

"Dr. Borie is an outstanding physician-scientist and clinical development leader whose experience spans discovery, development and advancement of innovative therapies for immune-mediated diseases," said Shao-Lee Lin, M.D., Ph.D., President and Chief Executive Officer of Cue Biopharma. "His deep expertise in immunology and proven leadership across biotechnology and global pharmaceutical organizations will be invaluable as we advance our portfolio of potential new and transformative therapies. I know that Dominic shares our commitment to scientific excellence, collaboration and improving the lives of patients. We are delighted to welcome him to Cue at this exciting stage in the company's evolution."

Prior to joining the biopharmaceutical industry, Dr. Borie served as Director of the Transplantation Immunology Laboratory at Stanford University and worked as a transplant surgeon in Paris, France. As part of his appointment package, Cue Biopharma granted him equity awards consisting of options to purchase 63,000 shares of company stock and 31,500 restricted stock units, both of which will vest over a four-year period subject to continued employment.